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During a study of the effects of a 
series of guanidine compounds on the 
esterolytic activities of thrombin, plas-
min, and streptokinase plus plasmin or 
plasminogen, it was found that one of 
these compounds, y-guanidinobutyric 
acid (GGBA), acted in several ways 
like e-aminocaproic acid (EACA). 
Neither compound had any inhibiting 
effects on the rate of hydrolysis 
of TAMe (p-toluenesulfonyl-L-arginine 
methyl ester), but both inhibited the 
activation of plasminogen by strepto-
kinase. EACA was the more potent in-
hibitor. Since EACA has been shown 
to inhibit the lysis of fibrin, primarily 
because it inhibits the activation of 
plasminogen (Ablondi et al., 1959, 
Alkjaersig, Fletcher, and Sherry, 
1959), GGBA was tested to see if it, 
too, would inhibit the lysis of blood 
clots. It was found to do so. In addi-
tion, it was found that GGBA also in-
hibits the formation of blood clots, 
which EACA does not do. These pre-
liminary results are reported here. 
Materials and Methods 
Fresh citrated blood from normal 
donors was used. Plasma was obtained 
by centrifuging the blood for 20 min-
utes at 2,500 rpm and 5°C. The eu-
globulin fraction of the plasma was 
precipitated by diluting the plasma 
with distilled water (1 part plasma, 14 
parts water) and was brought to pH 
5.35 with 0.1 N HCI. After centrifu-
gation for 3 minutes at 1,500 rpm and 
5°C, the supernatant was discarded and 
the precipitate was dissolved in a bar-
bital-saline buffer, pH 7.35 (Wintrobe, 
1961). It was tested immediately for 
clot formation and clot lysis. 
The contents of a vial of thrombin, 
(Thrombin Topical, bovine, Parke, 
Davis & Co., 1,000 NIH units) were 
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dissolved in 12.5 ml of glycerol and 
12.5 ml of 1.8% NaCl and refriger-
ated. Just before use the stock solution 
was diluted with 0.9% NaCl to con-
tain 2 or 4 NIH units per ml. Distilled 
water (4.0 ml) was added to a vial 
containing 100,000 units of strepto-
kinase (Varidase). Immediately before 
use it was diluted with 0.9% NaCl to 
contain either 1,000 or 2,000 units per 
ml. EACA was purchased from Mann 
Research Laboratories, and GGBA 
from Calbiochem. A 0.1 M solution of 
each compound was prepared in 0.9% 
NaCl. 
Results 
With the blood and plasma from 
four donors, inhibition of clot lysis was 
shown in the following way. To test 
tubes containing 0.1 ml of blood or 
plasma from a single donor, 0.1 ml of 
thrombin (4 NIH units per ml) was 
added and the contents were mixed. A 
clot formed immediately in each tube. 
After 15 minutes at room temperature 
(22-25°C), the following solutions 
were added to duplicate tubes: (1) 0.3 
ml of saline (0.9% NaCl), (2) 0.2 ml 
of saline plus 0.1 ml of EACA (0.1 M), 
(3) 0.2 ml of saline plus 0.1 ml of 
GGBA (0.1 M), (4) 0.2 ml of saline, 
15 minutes later 0.1 ml of streptoki-
nase (100 units per ml), (5) 0.1 ml of 
saline plus 0.1 ml of EACA (0.1 M), 
15 minutes later 0.1 ml of streptoki-
nase (1,000 units per ml), and (6) 0.1 
ml of saline plus 0.1 ml of GGBA (0.1 
M), 15 minutes later 0.1 ml of streptoki-
nase (1,000 units per ml). 
None of the clots in the first three 
sets of tubes lysed, even after remain-
ing at room temperature overnight. 
The clots in tubes (4) were completely 
or partially lysed in a few hours, and 
were completely lysed the next morn-
ing. The clots in tubes (5) and (6) we~e 
not lysed and apparently were com-
pletely intact when examined the next 
morning. 
When the experiments, as outlined 
in (4), (5), and (6), were repeated with 
either double the concentration of 
streptokinase or double the concentra-
tion of BACA or GGBA, the same re-
sults were obtained. There was lysis 
in tubes (4) and no lysis in tubes (5) 
or (6). 
Inhibition of clot formation was 
shown, with whole blood from two 
donors. To test tubes containing 0.1 ml 
of blood from a single donor were 
added: (1) 0.3 ml of saline, (2) 0.2 ml 
of saline plus 0.1 ml of BACA (0.1 
M), or (3) 0.2 ml of saline plus 0.1 ml 
of GGBA (0.1 M). After 15 minutes, 
0.1 ml of thrombin (4 NIH units per 
ml) was added to each tube. Four min-
utes later firm clots were present in all 
tubes containing saline or saline plus 
BACA. No clots were observed in any 
of the tubes containing GGBA. After 
20 minutes, an additional 0.1 ml of 
thrombin was added to the tubes con-
taining GGBA. Clots formed immedi-
ately. Firm clots were still present the 
following day in all tubes. 
A combined clotting and lysing ex-
periment was performed on the eu-
globulin fraction of the plasma from 
two donors. The euglobulin precipi-
tate was dissolved in 0.3 ml of buff-
ered saline. To duplicate tubes (con-
trols), 0.1 ml of saline was added. To 
other tubes, 0.1 ml BACA (0.1 M) or 
GGBA (0.1 M) was added. Thrombin, 
0.1 ml (2 units per ml) was added to 
each tube and the tubes were placed in 
a 37°C bath. After 15 minutes, firm 
clots were present in the control tubes 
and in the tubes containing BACA, but 
no clots were present in the tubes con-
taining GGBA. After 60 minutes, how-
ever, the latter tubes also contained 
clots. No evidence of lysis of any of 
the clots was seen even after the tubes 
had remained at 37°C for 5 hours. The 
tubes were then left at room tempera-
ture. The next morning no clots were 
found in the control tubes, but clots 
still remained in the tubes containing 
either BACA or GGBA. 
Discussion 
Low concentrations of GGBA are 
widely distributed in mammalian urine, 
brain, liver, and other tissues (Pisano, 
Abraham, and Udenfriend, 1963). 
These authors estimate that 0.05 and 
0.09 µ,moles of GGBA, respectively, 
are present in 1 gm, fresh weight, of 
rat brain and liver. GGBA has been 
reported to be of very low toxicity in 
rabbits, rats, and guinea pigs (Kamiya, 
Kiyota, and Kita, 1962). The finding 
that it inhibits the formation as well as 
the lysis of clots in the test tube sug-
gests that a guanidine-containing com-
pound may be involved in the physio-
logical regulation of blood clotting and 
lysing. GGBA itself is probably not 
the compound because it is not potent 
enough, judged from the preliminary 
experiments in vitro. Possibly a pep-
tide (or peptides), which is released 
when fibrinogen is changed to fibrin, 
may be the physiological regulating 
compound. 
From these and other data, it seems 
that GGBA may inhibit the hydrolysis 
of fibrinogen by thrombin, and in this 
way inhibit clot formation. BACA, on 
the other hand, has no effect on the ac-
tion of thrombin and therefore does 
not inhibit clot formation. In addition, 
both GGBA and BACA may react re-
versibly with plasminogen, changing it 
to a compound that cannot be acti-
vated to plasmin. In this way both 
compounds inhibit the lysis of clots. 
Experiments are now being done 
both in vitro and in vivo to establish 
quantitatively the extent of the inhibi-
tion of clot formation and lysis due to 
GGBA. Nagamatsu et al. (1963) have 
shown that esters of BACA are more 
potent inhibitors of clot lysis than is 
BACA itself. It is possible that esters 
of GGBA may also be more potent 
than GGBA as inhibitors of clot lysis 
and clot formation. These compounds 
or related ones may prove to be of 
value in preventing the formation of 
blood clots as well as controlling ex-
cessive fibrinolytic activity in vivo. 
Summary 
y-Guanidinobutyric acid inhibited 
the formation and the lysis of clots 
made from whole blood, plasma, or the 
euglobulin fraction of the plasma from 
several donors. e-Amino-caproic acid 
inhibited only the lysis of these clots, 
not their formation. 
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